Thoracic Cancers

Non-Small Cell Lung Cancer (NSCLC):

CIRB #H-33418/ CTSU #A151216 (ALCHEMIST): Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

ALCHEMIST Sub-studies:

CIRB #H-40717/ CTSU #A081801 (ACCIO): Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

CIRB #H-33425/ CTSU #E4512: A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein 

CIRB #H-40842/ CTSU #EA5181: Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

IRB #pend/ Merck #MK-7684A-006 (KEYVIBE-006): Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK- 7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC (not yet submitted to IRB)

Stage IV NSCLC Trials

Central IRB #H-42736/ Roche #BO42592 (SKYSCRAPER06): A Phase II/III, Randomized, Double-blind, Placebo-controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Central IRB #H-40642/ Janssen #NSC1001: An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer

CIRB #H-36723/ NRG #LU002: Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial (temporary closure)

Small Cell Lung Cancer (SCLC):

CIRB #H-40325/ SWOG #S1827 (MAVERICK): MRI Brain Surveillance Alone versus MRI Surveillance and Prophylactic Cranial Irradiation: A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

CIRB #H-41197/ NRG #LU007 (RAPTOR): RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial

CIRB #H-42287/ NRG #CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer (pending)

Esophageal/Stomach:

CIRB H-43647/ CTSU #A022102: Randomized Phase III Trial of mFOLFIRINOX vs. FOLFOX With Nivolumab for First-Line Treatment of Metastatic HER2- Gastroesophageal Adenocarcinoma (pending IRB approval)

CIRB H-42109/ CTSU #EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma (temporary closure)

Metastatic/Advanced 2nd+ Line Solid Tumors:

KRAS/NRAS/HRAS/BRAF positive
CIRB #H-42956/ ETCTN #10449: A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (pending)